Cargando…

Effects of Regulation on Carbapenem Prescription in a Large Teaching Hospital in China: An Interrupted Time Series Analysis, 2016–2018

PURPOSE: Carbapenem resistance due to the overuse of carbapenems has become a public health problem worldwide, particularly in low- and middle-income countries (LMICs). However, there are few policies guiding carbapenem prescription, and their effectiveness is still unclear. A regulation targeting c...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Lewei, Du, Yaling, Wang, Xuemei, Zhang, Xinping, Liu, Chenxi, Liu, Junjie, Peng, Xi, Guo, Xinhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364849/
https://www.ncbi.nlm.nih.gov/pubmed/34408453
http://dx.doi.org/10.2147/IDR.S322938
_version_ 1783738599105101824
author Xie, Lewei
Du, Yaling
Wang, Xuemei
Zhang, Xinping
Liu, Chenxi
Liu, Junjie
Peng, Xi
Guo, Xinhong
author_facet Xie, Lewei
Du, Yaling
Wang, Xuemei
Zhang, Xinping
Liu, Chenxi
Liu, Junjie
Peng, Xi
Guo, Xinhong
author_sort Xie, Lewei
collection PubMed
description PURPOSE: Carbapenem resistance due to the overuse of carbapenems has become a public health problem worldwide, particularly in low- and middle-income countries (LMICs). However, there are few policies guiding carbapenem prescription, and their effectiveness is still unclear. A regulation targeting carbapenem prescription was implemented in March 2017 in China. This study aimed to assess the effects of the regulation for providing evidence on the prudent use of carbapenems. PATIENTS AND METHODS: This was an interventional, retrospective study started in January 2017. The intervention covered establishing performance appraisal indicators, special authorisation, strict prescribing restrictions, and dedicated supervision, particularly in the intensive care unit (ICU). Data on adult inpatients who received at least one carbapenems were extracted from January 2016 to December 2018. Segmented regression analysis was performed to evaluate the effect of the regulation. RESULTS: A total of 2005 inpatients received carbapenems. Segmented regression models showed an immediate decline in the intensity of antibiotic consumption (IAC) of carbapenems (coefficient = −9.65, p < 0.001), particularly imipenem (coefficient = −6.82, p = 0.002), and the antibiotic consumption of carbapenems (coefficient = −133.60, p = 0.003) in the ICU. And there is a decreasing trend in the IAC of meropenem (coefficient = −0.03, p = 0.008) in all departments. Furthermore, the IAC of carbapenems and imipenem (coefficient = −0.36, p = 0.035; coefficient = −0.49, p = 0.025, respectively), and the average length of stay (ALoS) (coefficient = −0.73, p < 0.001) showed downward trends in the ICU. CONCLUSION: The intervention effectively reduced the IAC of carbapenems and imipenem, carbapenem consumption and the ALoS in the ICU, and the IAC of meropenem in all departments. The effects of the intervention were significant in the ICU, which indicated an urgent need for stronger regulations focusing on critical departments in the future.
format Online
Article
Text
id pubmed-8364849
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83648492021-08-17 Effects of Regulation on Carbapenem Prescription in a Large Teaching Hospital in China: An Interrupted Time Series Analysis, 2016–2018 Xie, Lewei Du, Yaling Wang, Xuemei Zhang, Xinping Liu, Chenxi Liu, Junjie Peng, Xi Guo, Xinhong Infect Drug Resist Original Research PURPOSE: Carbapenem resistance due to the overuse of carbapenems has become a public health problem worldwide, particularly in low- and middle-income countries (LMICs). However, there are few policies guiding carbapenem prescription, and their effectiveness is still unclear. A regulation targeting carbapenem prescription was implemented in March 2017 in China. This study aimed to assess the effects of the regulation for providing evidence on the prudent use of carbapenems. PATIENTS AND METHODS: This was an interventional, retrospective study started in January 2017. The intervention covered establishing performance appraisal indicators, special authorisation, strict prescribing restrictions, and dedicated supervision, particularly in the intensive care unit (ICU). Data on adult inpatients who received at least one carbapenems were extracted from January 2016 to December 2018. Segmented regression analysis was performed to evaluate the effect of the regulation. RESULTS: A total of 2005 inpatients received carbapenems. Segmented regression models showed an immediate decline in the intensity of antibiotic consumption (IAC) of carbapenems (coefficient = −9.65, p < 0.001), particularly imipenem (coefficient = −6.82, p = 0.002), and the antibiotic consumption of carbapenems (coefficient = −133.60, p = 0.003) in the ICU. And there is a decreasing trend in the IAC of meropenem (coefficient = −0.03, p = 0.008) in all departments. Furthermore, the IAC of carbapenems and imipenem (coefficient = −0.36, p = 0.035; coefficient = −0.49, p = 0.025, respectively), and the average length of stay (ALoS) (coefficient = −0.73, p < 0.001) showed downward trends in the ICU. CONCLUSION: The intervention effectively reduced the IAC of carbapenems and imipenem, carbapenem consumption and the ALoS in the ICU, and the IAC of meropenem in all departments. The effects of the intervention were significant in the ICU, which indicated an urgent need for stronger regulations focusing on critical departments in the future. Dove 2021-08-11 /pmc/articles/PMC8364849/ /pubmed/34408453 http://dx.doi.org/10.2147/IDR.S322938 Text en © 2021 Xie et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Xie, Lewei
Du, Yaling
Wang, Xuemei
Zhang, Xinping
Liu, Chenxi
Liu, Junjie
Peng, Xi
Guo, Xinhong
Effects of Regulation on Carbapenem Prescription in a Large Teaching Hospital in China: An Interrupted Time Series Analysis, 2016–2018
title Effects of Regulation on Carbapenem Prescription in a Large Teaching Hospital in China: An Interrupted Time Series Analysis, 2016–2018
title_full Effects of Regulation on Carbapenem Prescription in a Large Teaching Hospital in China: An Interrupted Time Series Analysis, 2016–2018
title_fullStr Effects of Regulation on Carbapenem Prescription in a Large Teaching Hospital in China: An Interrupted Time Series Analysis, 2016–2018
title_full_unstemmed Effects of Regulation on Carbapenem Prescription in a Large Teaching Hospital in China: An Interrupted Time Series Analysis, 2016–2018
title_short Effects of Regulation on Carbapenem Prescription in a Large Teaching Hospital in China: An Interrupted Time Series Analysis, 2016–2018
title_sort effects of regulation on carbapenem prescription in a large teaching hospital in china: an interrupted time series analysis, 2016–2018
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364849/
https://www.ncbi.nlm.nih.gov/pubmed/34408453
http://dx.doi.org/10.2147/IDR.S322938
work_keys_str_mv AT xielewei effectsofregulationoncarbapenemprescriptioninalargeteachinghospitalinchinaaninterruptedtimeseriesanalysis20162018
AT duyaling effectsofregulationoncarbapenemprescriptioninalargeteachinghospitalinchinaaninterruptedtimeseriesanalysis20162018
AT wangxuemei effectsofregulationoncarbapenemprescriptioninalargeteachinghospitalinchinaaninterruptedtimeseriesanalysis20162018
AT zhangxinping effectsofregulationoncarbapenemprescriptioninalargeteachinghospitalinchinaaninterruptedtimeseriesanalysis20162018
AT liuchenxi effectsofregulationoncarbapenemprescriptioninalargeteachinghospitalinchinaaninterruptedtimeseriesanalysis20162018
AT liujunjie effectsofregulationoncarbapenemprescriptioninalargeteachinghospitalinchinaaninterruptedtimeseriesanalysis20162018
AT pengxi effectsofregulationoncarbapenemprescriptioninalargeteachinghospitalinchinaaninterruptedtimeseriesanalysis20162018
AT guoxinhong effectsofregulationoncarbapenemprescriptioninalargeteachinghospitalinchinaaninterruptedtimeseriesanalysis20162018